ニュース

A spike in facility sales to outsourcing companies points to an industry need for greater flexibility.

The market adage “Sell in May and Go Away” rarely fits a single name cleanly. Eli Lilly (NYSE: LLY) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim. The Setup: A ... Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom

Eli Lilly's Omvoh (mirikizumab) has shown durable disease clearance over four years in patients with moderately to severely active ulcerative colitis. The long term data adds to existing evidence on Omvoh's efficacy and safety in inflammatory bowel disease. The results reinforce Eli Lilly's position in immunology and provide new information for clinicians and patients considering chronic treatment options. Eli Lilly (NYSE:LLY) enters this update with Omvoh's four year results adding another...

Exploring PRIMECAP Management (Trades, Portfolio)'s Recent 13F Filing and Investment Strategies

The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Eli Lilly and Company is one of the best cancer stocks. TheFly reported on May 5 that Barclays increased its valuation outlook for LLY, raising the price target to $1,400 from $1,350 while maintaining an Overweight rating. The […]

The tech sector has a record-high market cap of over $23 trillion, a 37% weighting in the S&P 500, the largest percentage ever.

Eli Lilly faces challenges in the GLP-1 market, with Novo Nordisk gaining a timing advantage in both injectable and oral drug approvals.

If it feels like growth stocks can’t continue their outperformance much longer, ignore that feeling. The Vanguard S&P 500 Growth Index Fund Exchange-Traded Fund, home to companies with high sales growth including Nvidia Advanced Micro Devices Microsoft and Eli Lilly is up 13% in the past month. A couple of factors have driven the performance of the growth stocks.

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Eli Lilly CFO Lucas Montrace joins Ashley Mastronardi on NYSE Live to discuss his YOY Revenue Beat

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story. Blowout Quarter Meets a Methodical Rebuild Lilly’s Q1 2026 ... Pfizer vs Eli Lilly: Different Bets on Pharma M&A

Eli Lilly and Company ( NYSE:LLY ) is about to trade ex-dividend in the next 3 days. The ex-dividend date occurs one...

Hims & Hers Health (NYSE:HIMS) has launched Labs AI, an AI care agent that provides users with personalized, clinically vetted interpretations of their lab results. The company is also expanding into FDA-approved GLP-1 weight loss medications through partnerships with major pharmaceutical companies, including Novo Nordisk and Eli Lilly. These moves come as NYSE:HIMS trades at $25.65, with the stock up 31.5% over the past 30 days but down 23.2% year to date and 50.1% over the past year. The...

The weight loss drug market is on track to reach almost $100 billion.

There's a reason the world's most patient investors love dividend stocks. Market movements heavily influence a stock's capital-gains potential in a given year. But dividends are usually paid whether the broader market is up or down, and that dependability is a big reason to factor them in when ...

NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.

BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to discuss the battle for GLP-1 dominance between Novo Nordisk (NVO) and Eli Lilly (LLY).

The competition is far behind.

Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook. On the earnings call, Co-Founder and CEO Sean D

Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can Lilly compete with copies of its own drug?

The Indianapolis-based company expanded its spend to ensure it can meet growing demand for genetic therapies and weight-loss drugs.

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. The offering, which initially targeted $8 billion, saw high investor demand following […]

Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. We did some...

In recent days, attention has centred on AbCellera Biologics ahead of its upcoming Q1 earnings call and the May 11, 2026 Phase 1 interim data update for ABCL635, a clinical candidate targeting menopause-related vasomotor symptoms. Investor optimism has been reinforced by analyst commentary on the potential competitiveness of ABCL635, growing insider and institutional interest, and AbCellera’s progress in advancing 19 molecules into clinical development across internal and partnered...